Moderna Stock Forecast
NASDAQ: MRNAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Pre-market: 195.56 -0.73%
MRNA analyst consensus
Consensus (23 analysts)
hold
Avg. price target
$121.00-38.58%
- Strong buy 1
- Buy 4
- Hold 15
- Sell 2
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 23 Wall Street analysts covering Moderna (2026-10-07), 5 rate the stock a buy or strong buy, 15 rate it a hold and 3 rate it a sell or strong sell, for a consensus rating of "hold". The average 12-month price target is $121.00, with a high estimate of $170.00 and a low estimate of $45.00. The average target implies downside of 38.6% from the current price of $197.00.
The spread between the highest and lowest targets is 277.8%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for MRNA.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 1 | 4% |
| Buy | 4 | 17% |
| Hold | 15 | 65% |
| Sell | 2 | 9% |
| Strong sell | 1 | 4% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $45.00 | -77.16% |
| Average target | $121.00 | -38.58% |
| High target | $170.00 | -13.71% |